4D Molecular Therapeutics (FDMT) Depreciation and Depletion (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Depreciation and Depletion data on file, last reported at $1.3 million in Q1 2026.

• On a quarterly basis, Depreciation and Depletion changed 0.0% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $5.2 million, a 6.12% increase from a year earlier, with the FY2025 full-year figure at $5.2 million, up 8.33% from the prior year.
• Depreciation and Depletion for Q1 2026 stood at $1.3 million, roughly flat from $1.3 million in the prior quarter.
• Over the last five years, Depreciation and Depletion for FDMT reached as high as $1.3 million in Q4 2023 and fell as low as $400000.0 in Q1 2022.
• Historically, Depreciation and Depletion has averaged $1.1 million across 5 years, with a median of $1.2 million in 2024.
• Across the five-year window, Depreciation and Depletion soared 150.0% in 2022 and retreated 7.69% in 2024, its largest moves.
• Year by year, Depreciation and Depletion stood at $1.0 million in 2022, then gained by 30.0% to $1.3 million in 2023, then declined by 7.69% to $1.2 million in 2024, then increased by 8.33% to $1.3 million in 2025, then changed by 0.0% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Depreciation and Depletion figures were $1.3 million in Q1 2026, $1.3 million in Q4 2025, and $1.3 million in Q3 2025.